TREPROSTINIL SODIUM | N213005 | LIQUIDIA TECHNOLOGIES INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| M.D.N.C. | 2025-05-09 | Active | — | |
| D. Del. | 2023-09-05 | Active | — | |
| D. Del. | 2020-06-04 | Terminated 2022-09-09 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Hyman, Phelps & McNamara, P.C. on behalf of United Ther... FDA-2024-P-2326 · 9 docket documents The law firm Hyman, Phelps & McNamara filed this citizen petition on behalf of United Therapeutics Corporation requesting that FDA rescind its tentative approval of Liquidia Technologies' section 505(b)(2) NDA for YUTREPIA, issue a Complete Response Letter, and withhold final approval unless Liquidi | 505(q) | 2024-05-14 | Denied | United Therapeutics Corporation |
Source: Regulations.gov. FDA citizen petitions matched by application number.